Drug intelligence / Profile preview

ABBV-990

Development stage: Discontinued
Lead developer: AbbVie
Modality: Small Molecules
Administration: Oral

Overview

ABBV-990 is an investigational oral antiviral drug developed by AbbVie for the treatment of SARS-CoV-2 infection (COVID-19). Its precise mechanism of action has not been defined or disclosed publicly. The drug was classified as a new molecular entity and entered phase 1 clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. As of late 2022, development was discontinued following termination of a phase 1 trial due to a company decision to re-evaluate the risk versus benefit profile[1][3][8].

Other names: ABBV 990ABBV990ABBV-990

Beyond the preview

Go deeper on ABBV-990.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABBV-990.

Explore the full profile